Latvia is actively working on initiatives to implement Real-World Evidence (RWE) and Real-World Data (RWD) in its healthcare system, with a focus on improving healthcare decision-making and enhancing the use of health technology assessment.
The Innovative Medicines Initiative (IMI) has set up the GetReal Initiative project to drive the adoption of RWE in healthcare decision-making across Europe, including Latvia. This initiative aims to tackle challenges related to data discoverability, quality, and accessibility, and bridge the gap between RWE and conventional randomised controlled trial approaches. It also offers education and training resources through the GetReal Academy.
In Latvia, there is no formal requirement for RWD submission within the reimbursement dossier. The evidence required for the decision-making process should be collected through randomized controlled clinical trials and is considered for decisions only when the results are published. However, RWD can be a supportive argument for decision-makers. The Center of Disease Prevention and Control (CDPC) is the main institution responsible for collecting and summarizing all health-related data in Latvia.
The European Commission is supporting Latvia with projects in the areas of development of public sector innovation and digitalisation, including improving the use of health technology assessment in decision-making. This support has addressed a broad range of policy areas, including healthcare, better governance and public administration, and justice.
Latvia could still stand to increase the use of real-world healthcare data to inform biomedical research and evaluation. A “learning healthcare system” based on electronic health records and other routinely collected data holds large promises for facilitating medical research and improving effective and efficient use of medicines, is at an early stage in Latvia.
In conclusion, while Latvia has made strides in implementing RWE and RWD initiatives, there is still room for growth and development in this area. The country is actively participating in European-wide initiatives and projects to enhance the use of RWE and RWD in healthcare decision-making and is working towards a learning healthcare system that leverages these data sources.
Share this story...
Real World Evidence (RWE) 201 – Beyond Clinical Trials: Health Canada’s Commitment to Real World Evidence
RWE 201 - Beyond Clinical Trials: Health Canada's Commitment to Real World Evidence Health Canada is dedicated to enhancing drug accessibility, affordability, and correct usage within the country. To [...]
Real World Evidence (RWE) 201 – A Tale of Two Regulatory Paths: Non-Interventional Studies in the USA
RWE 201 - A Tale of Two Regulatory Paths: Non-Interventional Studies in the USA Non-interventional studies are different from randomized controlled trials (RCTs). Instead of actively intervening in a [...]
Real World Evidence (RWE) 201 – FDA’s Advancing RWE Program
RWE 201 - FDA's Advancing RWE Program Real-world evidence is transforming the regulatory landscape, enabling the FDA to make informed decisions based on robust data from real-world settings. [...]
Real World Evidence (RWE) 201 – FDA’s RWE Considerations Draft Guidance
RWE 201 - FDA's RWE Considerations Draft Guidance The 21st Century Cures Act, signed into law in 2016, mandated the FDA to establish a framework for the evaluation of [...]
Real World Evidence 201 – FDAs RWE Framework
RWE 201 - FDAs RWE Framework Real World Evidence (RWE) 201 – FDAs RWE Framework RWE 201: https://rwr-regs.com/rwe-201/ The FDA's Real-World Evidence (RWE) Program framework, established under the [...]
Real World Evidence 201 – The 21st Century Cures Act
RWE 201 - The 21st Century Cures Act The 21st Century Cures Act (CURES 1.0), signed into law in the U.S. in December 2016, aimed to accelerate [...]







